Finch Therapeutics Group Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Matt Blischak

Amministratore delegato

US$775.7k

Compenso totale

Percentuale dello stipendio del CEO	32.5%
Mandato del CEO	1.5yrs
Proprietà del CEO	n/a
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	6.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Sep 01

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Aug 25

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

Aug 11

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Mar 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Dec 15

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Aug 28

Finch Therapeutics: Gut Instinct Says Buy

Jun 14

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Matt Blischak rispetto agli utili di Finch Therapeutics Group?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$776k	US$252k	-US$75m

Compensazione vs Mercato: La retribuzione totale di Matt ($USD 775.65K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 647.72K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Matt con le performance aziendali.

AMMINISTRATORE DELEGATO

Matt Blischak (61 yo)

1.5yrs

Mandato

US$775,651

Compensazione

Mr. Matthew P. Blischak, also known as Matt, JD, serves as Chief Executive Officer of Finch Therapeutics Group, Inc. since May 16, 2023 and serves as its President & Secretary since May 2023. He has intell...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Matthew Blischak	President	1.5yrs	US$775.65k	Nessun dato
Lance Thibault	Chief Financial Officer	1.5yrs	US$168.79k	Nessun dato
James Sigler	Executive Vice President of CMC	6.8yrs	Nessun dato	Nessun dato

1.5yrs

Durata media

61yo

Età media

Gestione esperta: Il team dirigenziale di FNCH non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffery Smisek	Independent Director	7.8yrs	US$2.29k	2.63% $ 509.1k
Chris Shumway	Independent Director	4.2yrs	US$2.29k	26.24% $ 5.1m
Christian Lange	Independent Chair	7.2yrs	US$2.29k	0% $ 0
Domenic Ferrante	Independent Director	5.2yrs	US$2.29k	1.32% $ 255.5k

6.2yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di FNCH sono considerati esperti (durata media dell'incarico 6.2 anni).

Finch Therapeutics Group Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

High number of new directors

Finch Therapeutics Group, Inc. Announces Executive Appointments

High number of new directors

Key Executive recently bought US$12m worth of stock

Recent updates

Finch Therapeutics Files Form 15

Finch Therapeutics to Delist Its Common Stock from the Nasdaq Global Select Market on or About October 31, 2024 and Announces SEC Deregistration

Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index

Finch Therapeutics Group Receives the Delisting Letter from the Office of the General Counsel of Nasdaq Notifying the Listing Panel Determines to Delist the Company from Nasdaq

Nasdaq Listing Qualifications Department Issues an Additional Staff Determination to Finch Therapeutics Group for Continued Non-Compliance with the Market Value of Publicly Held Shares Rule

Finch Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Requirements of Nasdaq Listing Rule 5605(c)(2)

The Nasdaq Stock Market LLC Notifies Finch Therapeutics Regarding Company’s Status as 'Public Shell'

Finch Therapeutics Group Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

Finch Therapeutics Announces 1-for-30 Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

First quarter 2023 earnings released: US$1.33 loss per share (vs US$0.52 loss in 1Q 2022)

Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

Price target decreased to US$12.00

Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

High number of new directors

Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 2500 Value Index

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

Price target decreased to US$27.67

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Finch Therapeutics Group, Inc. Pauses Enrollment in PRISM4 Its Phase 3 Clinical Trial of CP101 in Recurrent C. Difficile Infection

Finch Therapeutics Group, Inc. Announces Executive Appointments

Finch Therapeutics Group, Inc. Announces U.S. Patent and Trademark Office Grants Two New Patents for FIN-211

High number of new directors

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Third quarter 2021 earnings released: US$0.21 loss per share

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Finch Therapeutics: Gut Instinct Says Buy

Key Executive recently bought US$12m worth of stock

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media